What cervical cancer trials are currently recruiting?

There are 328 recruiting interventional trials for cervical cancer including pembrolizumab + chemoradiotherapy in locally advanced disease (KEYNOTE-A18-style designs), induction pembrolizumab + chemotherapy before chemoRT, PD-1/CTLA-4 bispecific antibodies (cadonilimab, volrustomig, QL1706, MEDI5752) in Phase 3 trials, TROP2 antibody-drug conjugates (sacituzumab tirumotecan / MK-2870) and HER3 ADCs (HER3-DXd / patritumab deruxtecan) after pembrolizumab progression, TIL cell therapy (GT101), and tisotumab vedotin (Tivdak) combinations.

What is the standard of care for cervical cancer in 2026?

Treatment depends on FIGO stage. Early-stage disease (IA-IB1): surgery (radical hysterectomy with lymph node assessment) for fertility-preserving cases or definitive chemoradiation. Locally advanced (IB3-IVA): concurrent cisplatin-based chemoradiation plus brachytherapy, and since KEYNOTE-A18 (2024) the standard now includes pembrolizumab added before, during, and after chemoradiation in high-risk patients. Persistent, recurrent, or metastatic disease: first-line pembrolizumab + paclitaxel + carboplatin or cisplatin, with or without bevacizumab (KEYNOTE-826). After progression on pembrolizumab: tisotumab vedotin (Tivdak), an FDA-approved tissue factor-targeted ADC.

Cervical Cancer Clinical Trials (May 2026): 328 Recruiting Interventional Studies

Last updated: May 17, 2026

Current Clinical Trial Landscape

About cervical cancer:

Roughly 13,000 new cases per year in the US, ~600,000 worldwide. About 95% are HPV-associated, mostly squamous cell carcinoma (HPV-16 and HPV-18 are the dominant types). The remaining ~5% are HPV-independent and tend to behave more aggressively. The disease has a meaningful global burden in Asia-Pacific, sub-Saharan Africa, and Latin America where HPV vaccination + screening coverage is lower.

Active research areas in 2026:

Pembrolizumab added to concurrent chemoradiation in high-risk locally advanced disease (KEYNOTE-A18 set the new standard in 2024; multiple Phase 3 trials test similar designs with other PD-1 inhibitors)
Induction immunotherapy + chemotherapy before chemoradiation (sequencing question)
PD-1/CTLA-4 bispecific antibodies (cadonilimab, volrustomig, QL1706, MEDI5752) — multiple Phase 3 trials in locally advanced and high-risk disease
TROP2 antibody-drug conjugates (sacituzumab tirumotecan / MK-2870) in Phase 3 after pembrolizumab progression — competing with the FDA-approved tisotumab vedotin (Tivdak)
HER3 antibody-drug conjugates (patritumab deruxtecan / HER3-DXd) in expanded basket trials
TIL (tumor-infiltrating lymphocyte) cell therapy for recurrent/metastatic disease after multiple lines
HPV-targeted therapies (therapeutic vaccines, HPV-specific T-cell therapy)

Standard of care (2026): Early-stage (FIGO IA–IB1): radical hysterectomy or definitive chemoradiation. Locally advanced (IB3–IVA): cisplatin-based chemoradiation + brachytherapy + pembrolizumab before/during/after chemoRT (KEYNOTE-A18). Recurrent / metastatic, first-line: pembrolizumab + paclitaxel + carboplatin or cisplatin ± bevacizumab (KEYNOTE-826). After pembrolizumab progression: tisotumab vedotin (Tivdak, FDA-approved 2024).

Recruiting Trials by Treatment Setting

Locally Advanced (Curative Intent)

For FIGO stage IB3–IVA disease where chemoradiation + brachytherapy is the curative-intent treatment, now with immunotherapy additions per the 2024 KEYNOTE-A18 standard:

Anti-PD-1 + chemoRT (Phase 3 KEYNOTE-A18-style designs):
- NCT07168200 - Adebrelimab + concurrent chemoRT in locally advanced cervical cancer (Phase 3)
- NCT07061977 - Induction pembrolizumab + chemotherapy → pembrolizumab + chemoRT (Phase 3, sequencing study)
PD-1/CTLA-4 bispecific antibodies + chemo (Phase 3):
- NCT07400536 - Cadonilimab + chemotherapy in locally advanced cervical cancer (Phase 3)
- NCT06079671 - Volrustomig in high-risk locally advanced cervical cancer (Phase 3)
Surgical / radiation optimization:
- NCT05581121 - Para-aortic lymphadenectomy in locally advanced cervical cancer (Phase 3)
- NCT07276360 - Hypofractionated radiotherapy for locally advanced cervical cancer (Phase 2)

Recurrent or Metastatic — First-Line

For untreated metastatic or recurrent disease. KEYNOTE-826 established pembrolizumab + chemo ± bevacizumab as standard; trials test what comes next:

NCT07216703 - Sacituzumab tirumotecan (MK-2870, TROP2 ADC) + pembrolizumab in 1L recurrent/metastatic (Phase 3)
NCT06266338 - Pembrolizumab + lenvatinib in metastatic and recurrent cervix cancer (Phase 2)
NCT07256236 - SKB264 (TROP2 ADC) + QL1706 (PD-1/CTLA-4 bispecific) in recurrent/metastatic (Phase 2)
NCT06925724 - Ivonescimab (PD-1/VEGF bispecific) in cervical + endometrial cancers (Phase 2)

After Pembrolizumab / Post-Platinum

For patients who have progressed on pembrolizumab + chemo. ADC era is the dominant theme:

NCT06459180 - Sacituzumab tirumotecan (MK-2870) monotherapy vs investigator's choice chemo after pembro (Phase 3)
NCT07418749 - SHR-A2102 vs investigator's choice chemotherapy (Phase 3)
NCT06769152 - HLX43 (PD-L1 ADC) in recurrent/metastatic cervical (Phase 2)
NCT06172478 - HER3-DXd (patritumab deruxtecan) in HER3-expressing solid tumors including cervical (Phase 2)

Cell Therapy and HPV-Targeted Approaches

Cellular therapy is emerging for cervical cancer because HPV viral antigens make these tumors uniquely targetable:

NCT06241781 - GT101 autologous TIL (tumor-infiltrating lymphocyte) therapy in recurrent/refractory cervical cancer (Phase 2)
NCT06157151 - PRGN-2009 (HPV-targeted off-the-shelf vaccine) + pembrolizumab in recurrent/metastatic HPV-associated cancers (Phase 2)

Trials by Treatment Approach

Checkpoint Inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4)

PD-1 inhibitors (pembrolizumab, cemiplimab, others) are now standard with chemo in 1L recurrent/metastatic and added to chemoRT in high-risk locally advanced disease. View all checkpoint inhibitor trials →

Bispecific Antibodies (PD-1/CTLA-4, PD-1/VEGF)

2026 is a major year for bispecific antibody Phase 3 readouts in cervical cancer. Cadonilimab, volrustomig, QL1706, and MEDI5752 are all PD-1/CTLA-4 bispecifics; ivonescimab is a PD-1/VEGF bispecific. View all bispecific trials →

Antibody-Drug Conjugates (ADCs)

Tisotumab vedotin (Tivdak), a tissue factor-targeted ADC, was the first FDA-approved ADC for cervical cancer (2024). Phase 3 trials now test next-generation TROP2 ADCs (sacituzumab tirumotecan / MK-2870, SKB264) and HER3 ADCs (HER3-DXd / patritumab deruxtecan). View all ADC trials →

TIL and Cellular Therapy

Tumor-infiltrating lymphocyte therapy (modeled on lifileucel in melanoma) is being tested in recurrent cervical cancer. HPV-specific T-cell receptor therapy is in earlier-phase development.

Showing selected notable trials. View all 328 recruiting interventional cervical cancer trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find cervical cancer clinical trials I'm eligible for?

Paste your medical summary into ClinTrialFinder to get AI-matched cervical cancer trials in minutes. The tool considers your FIGO stage, HPV status, histology (squamous cell vs adenocarcinoma), prior chemoradiation, and prior immunotherapy exposure.

Does HPV status affect cervical cancer treatment options?

Yes, increasingly. About 95% of cervical cancers are HPV-associated and tend to respond better to immunotherapy because HPV viral antigens make tumors more visible to the immune system. The ~5% that are HPV-independent are more aggressive and increasingly recognized as a separate prognostic group. Some 2026 trials stratify by HPV status; HPV-targeted therapies (vaccines, HPV-specific T cells) are HPV-specific by design.

What is the current standard of care for locally advanced cervical cancer?

Since KEYNOTE-A18 (2024), the standard for high-risk locally advanced disease (FIGO IB3-IVA with positive nodes or high tumor burden) is cisplatin-based chemoradiation plus brachytherapy with pembrolizumab added before, during, and after chemoRT. Multiple Phase 3 trials in 2026 test similar designs with other PD-1 inhibitors (adebrelimab) and PD-1/CTLA-4 bispecifics (cadonilimab, volrustomig).

What options exist after progression on pembrolizumab + chemo?

Tisotumab vedotin (Tivdak), a tissue factor-targeted antibody-drug conjugate, received FDA approval in 2024 and is the established post-pembrolizumab option. Phase 3 trials now test TROP2-targeted ADCs (sacituzumab tirumotecan / MK-2870) and other ADC classes in head-to-head comparisons. TIL cell therapy (GT101) is in Phase 2 for heavily-pretreated patients.

Find Cervical Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your FIGO stage, HPV status, and treatment history.

Find Matching Trials